Literature DB >> 15116861

[The global cardiovascular risk chart].

Simona Giampaoli1, Luigi Palmieri, Paolo Chiodini, Giancarlo Cesana, Marco Ferrario, Salvatore Panico, Lorenza Pilotto, Roberto Sega, Diego Vanuzzo.   

Abstract

BACKGROUND: Risk charts, built through risk functions deriving from longitudinal studies, are used in order to identify individuals at high risk for cardiovascular disease. For this reason the function has been identified and the global cardiovascular risk chart of the CUORE Project has been prepared, using Italian data coming from different cohorts enrolled between the '80s and the '90s, whose risk factors had been collected by standardized procedures.
METHODS: The following risk factors have been used: age (10-year period, 40-49, 50-59, 60-69 years), gender (men and women), systolic blood pressure (< or = 129, 130-149, 150-169, > or = 170 mmHg), serum cholesterol (< or = 173, 174-212, 213-251, 252-290, > or = 291 mg/dl), smoking habit (yes, no) and presence of diabetes (yes, no); the first coronary or cerebrovascular event in people aged 40-69 years with no other previous cardiovascular events was considered as endpoint; survival has been assessed up to December 1998.
RESULTS: Out of 18,028 people aged 40-69 years with no previous cardiovascular events, 647 first major cardiovascular events have been identified and validated, 449 coronary and 198 cerebrovascular. Charts are divided according to men and women and to diabetics and non-diabetics respectively; the different colors represent the percent level of risk and go from light green (< 5% in 10 years for men, < 1% in 5 years for women), dark green (between 5 and 10% for men, between 1 and 3% for women), yellow (between 10 and 15% for men, between 3 and 5% for women), orange (between 15 and 20% for men, between 5 and 7% for women), red (between 20 and 30% for men, between 7 and 10% for women), violet (> 30% for men, > 10% for women).
CONCLUSIONS: The risk charts were built with data collected in recent years on men and women with a median follow-up of 10 years for men and 5 years for women, considering the first major fatal or non-fatal cardiovascular event as endpoint. Such a tool is easy to be applied by general practitioners and cardiologists in order to achieve a fast and objective evaluation of global cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15116861

Source DB:  PubMed          Journal:  Ital Heart J Suppl        ISSN: 1129-4728


  10 in total

Review 1.  Hypertensive retinopathy revisited: some answers, more questions.

Authors:  A Grosso; F Veglio; M Porta; F M Grignolo; T Y Wong
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

Review 2.  Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice.

Authors:  Roberto Volpe; Gianluca Sotis
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-05-01

3.  High prevalence of metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Domenico Malesci; Alferio Niglio; Gianna Angela Mennillo; Rosario Buono; Gabriele Valentini; Giovanni La Montagna
Journal:  Clin Rheumatol       Date:  2006-08-25       Impact factor: 2.980

4.  Plasma ochratoxin A levels, food consumption, and risk biomarkers of a representative sample of men and women from the Molise region in Italy.

Authors:  Romina di Giuseppe; Terenzio Bertuzzi; Filippo Rossi; Silvia Rastelli; Annalisa Mulazzi; Jessica Capraro; Amalia de Curtis; Licia Iacoviello; Amedeo Pietri
Journal:  Eur J Nutr       Date:  2011-10-29       Impact factor: 5.614

Review 5.  2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document.

Authors:  Massimo Volpe; Roberto Volpe; Giovanna Gallo; Vivianne Presta; Giuliano Tocci; Emanuela Folco; Andrea Peracino; Elena Tremoli; Bruno Trimarco
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-18

6.  Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study.

Authors:  Marco Bertolotti; Carlotta Franchi; Marco B L Rocchi; Andrea Miceli; M Vittoria Libbra; Alessandro Nobili; Giulia Lancellotti; Lucia Carulli; Chiara Mussi
Journal:  Drugs Aging       Date:  2017-04       Impact factor: 3.923

7.  Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Monica Lanzoni; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Antonio Gaddi; Alberto Vaccheri; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

8.  How artificial intelligence tools can be used to assess individual patient risk in cardiovascular disease: problems with the current methods.

Authors:  Enzo Grossi
Journal:  BMC Cardiovasc Disord       Date:  2006-05-03       Impact factor: 2.298

9.  Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?

Authors:  Daniele Santi; Michela Locaso; Antonio R Granata; Tommaso Trenti; Laura Roli; Chiara Pacchioni; Vincenzo Rochira; Cesare Carani; Manuela Simoni
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

Review 10.  The Role of Cardiovascular Risk Assessment in Preventive Medicine: A Perspective from Portugal Primary Health-Care Cardiovascular Risk Assessment.

Authors:  Paulo Santos
Journal:  J Environ Public Health       Date:  2020-01-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.